Skip to main content

Advertisement

SpringerLink
Log in

Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

We aimed to investigate the efficacy of denosumab for rheumatoid arthritis (RA). This study enrolled 70 RA patients who received denosumab 60 mg subcutaneous injection at baseline and at 6 months. Bone mineral densities (BMD) of the lumbar spine, total hip, femoral neck, and hand were measured by dual energy X-ray absorptiometry. Changes in total modified Sharp score (mTSS), erosion (EN) score, and joint space narrowing score at baseline from 12 months before and at 12 months from baseline. The mean values of BMD of the lumbar spine, total hip, femoral neck, and hand significantly increased by 7.3, 4.7, 3.9, and 5.4%, respectively, at 12 months. At 12 months from baseline, there were significant decreases in the values of mTSS (1.13 vs. 0.59; p = 0.002) and EN score (0.40 vs. 0.07; p < 0.001), compared with the values at baseline from 12 months before. The existing combined modality therapy with denosumab might be effective for osteoporosis and joint destruction in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kvien TK, Uhlig T (2005) Quality of life in rheumatoid arthritis. Scand J Rheumatol 34:333–341

    Article  PubMed  CAS  Google Scholar 

  2. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T (2005) Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 34:441–447

    Article  PubMed  CAS  Google Scholar 

  3. Masiero S, Boniolo A, Wassermann L, Machiedo H, Volante D, Punzi L (2007) Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. Clin Rheumatol 26:2043–2050

    Article  PubMed  Google Scholar 

  4. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108

    Article  PubMed  Google Scholar 

  5. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005) Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1:47–54

    Article  PubMed  CAS  Google Scholar 

  6. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176

    Article  PubMed  CAS  Google Scholar 

  7. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342

    Article  PubMed  CAS  Google Scholar 

  8. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495

    Article  PubMed  CAS  Google Scholar 

  9. van der Heijde DM (2000) Radiographic imaging: the ‘gold standard’ for assessment of disease progression in rheumatoid arthritis. Rheumatology 39:9–16

    Article  PubMed  Google Scholar 

  10. Van der Heijde D (2001) Radiographic progression in rheumatoid arthritis: dose it reflect outcome? Dose it reflect treatment? Ann Rheum Dis 60:47–50

    Google Scholar 

  11. Josse R, Khan A, Ngui D, Shapiro M (2013) Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin 29:205–216

    Article  PubMed  CAS  Google Scholar 

  12. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309

    Article  PubMed  CAS  Google Scholar 

  13. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983–990

    Article  PubMed  CAS  Google Scholar 

  14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 16:65–67

    Google Scholar 

  15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

    Article  PubMed  Google Scholar 

  16. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261–263

    PubMed  Google Scholar 

  17. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  PubMed  CAS  Google Scholar 

  19. Deodhar AA, Brabyn J, Pande I, Scott DL, Woolf AD (2003) Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis 62:767–770

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Dischereit G, Tarner IH, Müller-Ladner U, Lange U (2013) Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 32:377–381

    Article  PubMed  Google Scholar 

  21. Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898–1901

    Article  PubMed  CAS  Google Scholar 

  22. Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, Mueller-Schmucker S, Kroczek RA, Heinzerling L, Moser M, Mellor AL, David JP, Schett G (2014) T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. doi:10.1126/scitranslmed.3007764

    Article  PubMed  Google Scholar 

  23. Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 62:569–574

    Article  CAS  Google Scholar 

  24. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM (2004) The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 50:2082–2093

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Kamagaya General Hospital, 929-6 Hatsutomi, Kamagaya, Chiba, 273-0121, Japan

    Takeshi Mochizuki, Kosei Kawakami, Ryo Hiroshima, Naoko Koenuma & Mina Ishibashi

  2. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Koichiro Yano & Katsunori Ikari

  3. Department of Orthopaedic Surgery, Keio University, Tokyo, Japan

    Shigeki Momohara

Authors
  1. Takeshi Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koichiro Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsunori Ikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kosei Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryo Hiroshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoko Koenuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mina Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shigeki Momohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The sponsors were not involved in the: study design; collection, analysis, and interpretation of data, writing of the paper, and/or decision to submit the results for publication.

Corresponding author

Correspondence to Takeshi Mochizuki.

Ethics declarations

Conflict of interest

T. Mochizuki received honorariums for lectures from AbbVie, Inc., Asahi Kasei Pharma Corp., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., and Takeda Pharmaceutical Co., Ltd. K. Ikari received honorariums for lectures and/or unrestricted research Grants from AbbVie, Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Eisai Co., Ltd. Hisamitsu Pharmaceutical Co., Inc., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. S. Momohara received honorariums for lectures and/or unrestricted research Grants from AbbVie, Inc., Asahi Kasei Pharma Corp., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Nakashima Medical Co., Ltd., Santen Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. The other authors declare that they have no conflicts of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mochizuki, T., Yano, K., Ikari, K. et al. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis. J Bone Miner Metab 36, 431–438 (2018). https://doi.org/10.1007/s00774-017-0848-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-017-0848-1

Keywords

Search

Navigation